Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales fréquentes
Nom anglais: Cytochrome P-450 CYP2C9 Inducers
Descriptor UI:D065698
Tree Number:D27.505.519.349.320
Termes MeSH sélectionnés :
Recovery of Function
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Miklós Poór",
"url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu."
}
},
{
"@type": "Person",
"name": "Jian-Ping Cai",
"url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Slávka Bodnárová",
"url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Eszter Fliszár-Nyúl",
"url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Jian Liu",
"url": "https://questionsmedicales.fr/author/Jian%20Liu",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comparison of recovery of sheep, goats, and calves from reversible electrical head-only and head-to-body stunning for halal meat production.",
"datePublished": "2024-06-30",
"url": "https://questionsmedicales.fr/article/38946044",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/00480169.2024.2367532"
}
},
{
"@type": "ScholarlyArticle",
"name": "Defective recovery of QT dispersion due to no-reflow following acute interventional therapy in patients with ST-segment elevation myocardial infarction.",
"datePublished": "2024-06-18",
"url": "https://questionsmedicales.fr/article/38975003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/cdt-23-398"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hydrothermally Stimulated Molecular Interfaces for Augmented Electron Delocalization in Wet-Chemical Phosphorus Recovery from Incineration Ash of Sewage Sludge.",
"datePublished": "2024-06-08",
"url": "https://questionsmedicales.fr/article/38850558",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.est.4c03290"
}
},
{
"@type": "ScholarlyArticle",
"name": "Postoperative recovery after suspension suture placement at the site of esophagojejunal anastomosis after total gastrectomy: Comparison of two surgical techniques.",
"datePublished": "2024-06-05",
"url": "https://questionsmedicales.fr/article/38968063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3233/THC-231467"
}
},
{
"@type": "ScholarlyArticle",
"name": "Influence of nitrate supplementation on motor unit activity during recovery following a sustained ischemic contraction in recreationally active young males.",
"datePublished": "2024-05-29",
"url": "https://questionsmedicales.fr/article/38809323",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00394-024-03440-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"item": "https://questionsmedicales.fr/mesh/D065698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2C9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2C9 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe."
}
},
{
"@type": "Question",
"name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2C9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils informer leur médecin des médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Des tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement inapproprié ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques."
}
},
{
"@type": "Question",
"name": "Les changements de traitement doivent-ils être rapides ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements doivent être faits prudemment pour éviter des effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle la santé globale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans l'induction ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'induction ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique."
}
}
]
}
]
}
To compare the recovery of lambs, goats, and calves from head-only (HO) or high-frequency head-to-body stunning and evaluate the complementary use of behaviour and electroencephalography (EEG) to asse...
Six-month-old lambs, adult goats and calves (< 7 days old) were subjected to reversible head-only stunning (50 Hz, 1 A, 2 seconds) or reversible high-frequency head-to-body stunning (RHTB: HO followed...
The RHTB stun was reversible in all three species, although one sheep failed to recover and was euthanised. Both methods caused tonic and clonic convulsions in all species. Behavioural recovery of she...
Head-to-body stunning as applied here produced a reversible electrical stun in lambs, adult goats and young calves, although the benefits in terms of meat quality and operator safety are uncertain. Go...
For the purposes of pre-slaughter stunning of sheep, goats and young calves, recovery appears comparable between the two methods, with all but 1/63 animals in the behaviour study recovering normal fun...
Previous studies have suggested that adequate myocardial reperfusion after percutaneous coronary intervention (PCI) can improve the inhomogeneity of myocardial repolarization. However, it remains uncl...
A prospective case-control study was conducted. According to the inclusion criteria, 275 patients with STEMI who underwent primary PCI treatment at the First People's Hospital of Anqing affiliated to ...
In the non-NR group, there was a significant decrease from baseline in postprocedure QTd (48±17...
The NR phenomenon following primary PCI in patients with STEMI leads to the defective recovery of QTd and QTcd. Furthermore, ΔQTcd-R can be viewed as an effective indicator for evaluating the myocardi...
Wet-chemically recovering phosphorus (P) from sewage sludge incineration ash (SSIA) has already become a global initiative to address P deficit, but effectively isolating P from these accompanying met...
Despite improvements, survival rates for gastric cancer remain low, even in developed countries, confirming the role of primary and secondary prevention....
This study aims to demonstrate the role of additional suspension sutures on the esophagojejunal anastomosis (EJA) to strengthen the anastomosis, i.e., relieve the mechanical suture....
A retrospective cohort study was conducted from 2011 to 2022 at the Clinic for Surgery, University Clinical Center Tuzla, Bosnia and Herzegovina. The experimental group consisted of patients placed wi...
A total of 212 patients were included in the study: 87 in the experimental group with suspension sutures on the EJA and 125 in the control group without suspension sutures on the EJA. The two cohorts ...
Our study did not show a statistically significant difference between the two analyzed EJA techniques created with a circular stapler, when it comes to postoperative course and outcome in patients wit...
Dietary nitrate (NO...
In a randomized, double-blinded, cross-over design, 14 males (mean ± SD, 25 ± 6 years) completed two trials following 5 days of supplementation with NO...
The change in MUP area and MUFR, did not differ between conditions (all p > 0.05), but NIT elicited a reduction in MUP recovery time during brief isometric contractions (p < 0.001), and during recover...
These novel observations improve understanding of the effects of NO...
The study was registered on clinicaltrials.gov with ID of NCT05993715 on August 08, 2023....
To analyse whether the harmful effect of job demands on recovery can be alleviated by healthy lifestyle, psychological recovery experiences and job resources. We also describe their prevalence among e...
Cross-sectional study....
The data were collected using a self-report survey in 2020 in the health and social services sector organizations (n = 4478). Employees were classified as the following service types: general health a...
Poor recovery, high job demands, low appreciation and low autonomy in terms of worktime and breaks were more prevalent in eldercare. Employers could alleviate the risk of high job demands by offering ...
The study emphasizes the importance of appreciation in the health and social services sector context. Even with moderate levels of appreciation employers can protect employees from poor recovery from ...
Eldercare employees face continuous and accumulating work strain at the same time as the sector struggles against a labour shortage. One way to prevent the harmful consequences of strain is to enhance...
STROBE checklist....
No patient or public contribution....
Printed circuit boards (PCBs) make up a substantial amount of electronic waste (e-waste) generated annually. Waste PCBs contain high quantities of copper and gold in comparison to natural ores. As suc...
Acute kidney injury requiring dialysis (AKI-D) commonly occurs in the setting of multiple organ dysfunction syndrome (MODS). Continuous renal replacement therapy (CRRT) is the modality of choice for A...
Retrospective cohort....
Two large quarternary care pediatric hospitals....
Patients 26 y old or younger who received CRRT from 2014 to 2020, excluding patients with chronic kidney disease....
None....
Organ dysfunction was assessed using the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score. MODS was defined as greater than or equal to two organ dysfunctions. The primary outcome was major adve...
Ninety percent of critically ill children and young adults with AKI-D develop MODS by the start of CRRT. Lack of renal recovery is associated with specific extrarenal organ dysfunction and progressive...
The preparation of self-healing polyurethane elastomers (PUEs) incorporating dynamic bonds is of considerable practical significance. However, developing a PUE with outstanding mechanical properties a...
The impact of atmospheric deposition and environmental factors on catchment processes and water chemistry of 20 high-altitude Alpine lakes in Southern Switzerland was investigated over four decades. T...